Richard Nolan Townsend Sells 4,326 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 4,326 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $4.41, for a total transaction of $19,077.66. Following the sale, the chief executive officer now owns 220,119 shares of the company’s stock, valued at approximately $970,724.79. This represents a 1.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, December 10th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.20, for a total transaction of $20,500.00.

Lexeo Therapeutics Trading Down 3.5 %

Shares of Lexeo Therapeutics stock opened at $3.89 on Friday. The firm has a market capitalization of $128.64 million, a PE ratio of -1.23 and a beta of 2.99. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $5.70 and its 200 day moving average is $8.07. Lexeo Therapeutics, Inc. has a 1 year low of $3.84 and a 1 year high of $19.50.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in LXEO. Frazier Life Sciences Management L.P. bought a new stake in shares of Lexeo Therapeutics during the 3rd quarter valued at approximately $11,307,000. Janus Henderson Group PLC grew its holdings in shares of Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after purchasing an additional 599,203 shares during the last quarter. Altium Capital Management LLC bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at approximately $2,665,000. Point72 Asset Management L.P. grew its holdings in shares of Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Finally, Verition Fund Management LLC grew its holdings in shares of Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after purchasing an additional 355,928 shares during the last quarter. 60.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. HC Wainwright lifted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Chardan Capital lifted their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.80.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.